ZVRA

MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that it has submitted U.S. Patent No. 11,707,456 for MIPLYFFA® (arimoclomol) to the U.S. Food and Drug Administration for listing in the publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The patent expires on November 19,

8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 33,000 shares of the Company's common stock (the "Inducement Awards") to four new employees pursuant to the Company's 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee's start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee's continued employment o

4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will present at the H.C. Wainwright BioConnect Investor Conference in New York, NY on Tuesday, May 19, 2026, at 9:00 a.m. ET. Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the "Events & Presentations" page in the Investor Relations section of Zevra's website at investors.zevra.com. About Zevra Therapeutics, Inc. Zevra T

144 - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

10-Q - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

Q1 2026 net revenue of $36.2 million, a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to host conference call and webcast TODAY, May 6, 2026, at 4:30 p.m. ET BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the first quarter ended March 31, 2026. "We made meaningful progress across the business in the first quarter, led by continued performance for MIPLYFFA, underscoring

SCHEDULE 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the first quarter on Wednesday, May 6, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the "Events & Presentations" page in the Investor Relations section of Zevra's website at investors.zevra.com. To join via telephone, please use the following dial-in information: (800) 579-2543 (United States)+1 (78

DEF 14A - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

PRE 14A - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

SCHEDULE 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted as of March 18, 2026 an equity inducement award to Justin Renz, the Company's new Chief Financial Officer pursuant to the Company's 2023 Employment Inducement Award Plan (as amended and/or restated, the "Inducement Award Plan"). The equity award was approved by the Compensation Committee of the Board of Directors in accordance with Nasdaq Rule 5635(c)(4) and made as a material inducement to Mr. Renz upon acceptance of employment with Zevra. The C

4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

3 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

BTIG Research initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $23.00

8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreement under which Commave Therapeutics SA (Commave) will purchase Zevra's serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, for $50 million. "We are pleased to have reached a mutually beneficial agreement with Commave regarding the sale of our entire SDX portfolio," said Neil F. McFarlane, Zevra's President and Chief Executive Officer. "Over the years, we have enjoyed a productive partnership with Commave, and we are confident these programs are i

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (NASDAQ:ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing Program is designed to expand access to GeneDx's industry-leading ExomeDx™ test for patients with suspected Niemann-Pick disease type C, helping clinicians reach accurate diag

S-8 - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

10-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)